crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - lieky na liečbu chorôb kostí - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
furosemid fmk 40 mg
farmak international sp. z o.o., poľsko - furosemid - 50 - diuretica
furosemid medreg
medreg s.r.o., Česká republika - furosemid - 50 - diuretica
furosemide norameda 10 mg/ml injekčný/infúzny roztok
uab norameda, litva - furosemid - 50 - diuretica
furosemid-slovakofarma
zentiva a.s., slovensko - furosemid - 50 - diuretica
furosemid-slovakofarma forte
zentiva a.s., slovensko - furosemid - 50 - diuretica
furosemid kabi 20 mg/2 ml
fresenius kabi s.r.o., Česká republika - furosemid - 50 - diuretica
furosemid hameln 10 mg/ml injekčný roztok
hameln pharma gmbh, nemecko - furosemid - 50 - diuretica
furosemid bbp 10 mg/ml
bb pharma a.s., Česká republika - furosemid - 50 - diuretica
furosemid bbp 12,5 mg/ml
bb pharma a.s., Česká republika - furosemid - 50 - diuretica